Special Issue: Genomics and Model Organisms: New Horizons for Experimental Hematolog
Introducing Lead Guest Editor on Genomics: Bertie Gottgens and David Traver
Bertie Gottgens of Experimental Hematology’s Special Issue Genomics and Model Organisms: NEW HORIZONS FOR EXPERIMENTAL HEMATOLOGY, an official publication of the Society for Hematology and Stem Cells.
Prof Gottgens is the Professor of Molecular Haematology at the University of Cambridge. He studied Biochemistry at the University of Tübingen (1986-1991), followed by a DPhil in Molecular Biology at the University of Oxford (1992-1994). He is a Principal Investigator within the Wellcome Trust and MRC Cambridge Stem Cell Institute, and also a member of the Cambridge Cancer Centre.
His long-term research goal is to decipher the molecular hierarchy of transcriptional networks responsible for blood stem cell development, and how perturbation of these networks causes leukaemia. A particular strength of his research programme is the combination of genome-scale experimental approaches with bioinformatic analysis and mathematical modelling, to better understand regulatory networks in normal and leukaemic blood stem cells.
Stating on his role as Genomics Lead Guest editor he said: "This series aims to publish articles from leaders in this new and emerging field, with the explicit aim of providing guidance for others who are keen to take advantage of the new genomic technologies for their own research."
David Traver is Professor of Cellular and Molecular Medicine at the University of California, San Diego. He received the McDevitt Prize for his Ph.D. work in Immunology at Stanford University in 2000, and performed postdoctoral studies at Harvard University from 2000-2004 as a fellow of the Irvington Institute.
The Traver laboratory studies the formation of hematopoietic stem and progenitor cells, and how the progeny of these precursors function to provide immunity in the developing animal. Traver is the recipient of a number of awards, including Scholar Awards from the March of Dimes Foundation, the American Society of Hematology, the Sidney Kimmel Foundation for Cancer Research, and the Leukemia and Lymphoma Society.